Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64565111 in Severely Obese Subjects With Type 2 Diabetes
NCT03586830Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2018
- Primary completion
- Apr 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of efinopegdutide in obesity, type 2 diabetes mellitus (T2DM), sponsored by Janssen Pharmaceutical. Started Jun 2018; status: completed.
02
Drugs
efinopegdutide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03586830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03586830.